Tamtuvetmab
Based on 1 Customer Validation
Tamtuvetmab (AT-005) is a caninised blontuvetmab against CD52. Tamtuvetmab increases progression-free survival (PFS), exhibits in vivo efficacy in dogs with naïve T-cell lymphoma (LSA). Tamtuvetmab has been approved by veterinary.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 97%
- CAS No.: 1608122-71-9
- 분자량:146.346 kDa
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- 순도&문서
- References
-
Help & FAQs
Biological Activity
Caninized IgG2 Vkappa Clambda
Caninized
Canlupfam CD52
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:T-cell LSA Model in Dog[1]
-
Dosage:5 mg/mL, 7.5-30 mL; Dogs weighing for 2-15 kg received 7.5 mL, for 15.1-30 kg received 15 mL, for 30.1-45 kg received 22.5 mL, for 45.1-60 kg received 30 mL
-
Administration:Intravenous injection; 15-30 min
-
Result:Showed in vivo efficacy with severe side effect.
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
IgG2-Vkappa-Clambda
ELISA, FACS, Functional assay
Chemical Information
-
CAS No. 1608122-71-9
-
Appearance Liquid
-
분자량 146.346 kDa
-
Color Colorless to light yellow
-
SMILES
[Tamtuvetmab]
-
Synonyms
AT-005
-
선적
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
순도&문서
-
Data Sheet (257 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Musser ML, et al. Randomised trial evaluating chemotherapy alone or chemotherapy and a novel monoclonal antibody for canine T-cell lymphoma: A multicentre US study. Vet Rec Open. 2022 Nov 1;9(1):e49. [Content Brief]
[2]. Rhodes L. Changing innovation into a registered product: From concept to regulatory approval. Theriogenology. 2018 May;112:75-81. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Tamtuvetmab Related Classifications
HY-P99579 Related Classifications
Powered by Bioz